Rusnano, the group set up to promote Russia’s nanotechnology infrastructure, says nanodrug development partnership will improve patient access and cut cancer death rates across the country.
The US Food and Drug Administration (FDA) has issued guidance on the use of Bayesian analysis in clinical trials of medical devices and says the technique can cut costs and boost efficiency.
US CDMO Avrio Biopharmaceuticals’ new aseptic fill-and-finish facility in Irvine, California has been approved for the manufacture of biologics by state drug regulators.
Gerresheimer expects pharmaceutical packaging sales to grow but says performance of “cyclical” cosmetics and life science businesses is more difficult to predict.
The WHO has stopped sending free drugs to private hospitals and non-governmental organisations in Haiti after receiving reports that some institutions in the earthquake stricken country had begun to charge patients.
SIRO Clinpharm has formed an alliance with South Korea-based CRO DreamCIS to expand its clinical trial offering in Asia Pacific and provide clients with more options for patient recruitment.
The US FDA says its new screening system will expedite the importation of genuine drugs and help inspectors focus their efforts on “high risk” products.
Almost half of antimalarials in Senegal are substandard, according to a USP study which will be used by local regulators to focus efforts on high-risk products, brands and geographies.
The EFCG has welcomed the addition of excipient GMP requirements to the draft amendments of the EU falsified medicines directive but warned that deeper analysis is needed to establish which products warrant further regulation.
Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.
In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.
ClearTrial says information is power in trial talks and claims its CTO software helped biotech firm save 20 per cent of bid cost through more informed negotiations with its CRO.
Contract services major Quintiles will sell Movetis’ chronic constipation treatment Resolor (prucalopride) in Europe under a contract announced last week.
PRA International has entered into a partnership with Oncopartners and IBPC to accelerate the planning, start-up and patient recruitment of oncology trials in Latin America.
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
The global market for RFID products and services in the pharma industry will be worth $884m (€631m) in 2015, according to a report, but apprehensions about initial costs and return-on-investment need to be overcome.
Environmental certification of production facilities should be introduced to GMP legislation and sustainability risk assessments linked to marketing authorisations, according to a MPA report.
The SPMC of Sri Lanka is seeking a $10m (€7.1m) loan to buy high-speed tablet and capsule filling machines and ensure it can meet the island’s demand for safe medicines.
Indian CRO Ankur Drugs and Pharma is a step closer to stating production of Romaco’s Siebler StripTabs now the German firm developed a fully integrated manufacturing line.
Emergency relief groups in Haiti can expect to receive continued support from the drug industry, according to the International Federation of Pharmaceutical Manufacturers (IFPMA).
Indian drugmaker Lupin can start seeking US approval for new drugs made at its API plant in Mandideep, Bhopal after resolving the cGMP deficiencies that earned the facility a US FDA warning last year.
DSM Speciality Intermediates (DSI) is to close by the end of 2010, with activities at its production site ceasing in July, in response to pricing pressures caused by the rise of rivals in India and China.
Pharmaceutical packaging machinery manufacturer Sepha has reported a 33 per cent increase in sales for 2009, underpinned by strong growth in Asia and South America.
AMRI’s plant in Rensselaer, New York gained SafeBridge potent compound certification this week after an effort that spokesperson Andrea Schulz said istestament to the firm's "willingness to go the extra mile”.
Malgorzata Szerszeniewska, CEO of Central and Eastern Europe’s (CEE) “newest” CRO EastHorn, says maintaining ethical standards is crucial to sustaining the rapid patient recruitment rates that characterise the region.
Quotient Bioresearch has secured the supply of 14C labelled compounds for its customers ahead of its move to a new purpose built facility in Cardiff through an extension of its agreement with GE Healthcare (GEHC).
The EFPIA’s European Vaccine Manufacturers (EVM) group has denied allegations that its members were involved in hyping up the threat of the H1N1 pandemic to boost vaccine sales.
Quintiles Transnational has selected US ePRO solutions provider Invivodata to help it meet growing regulatory pressure to focus on the patient perspectives during trials.
New Jersey, US-based contractors Catalent Pharma Solutions and Compass Pharma Services expanded their respective blister pack offerings last week, both citing growing drug industry demand.
Latin America, new services and mid-sized pharma clients are targets for the incoming CEO of Clearstone Central Laboratories, who set out his vision for the business in an interview with Outsourcing-Pharma.
Lonza will shut down its API plant in Riverside, Pennsylvania, US by the end of the year as part of a plan to cut costs and shift small-molecule production to Asia.
Outsourcing-pharma presents a round up of all the latest deals and developments in the contract research space. This week Synexus closes ClinPharm deal, GVK joins ResearchPoint Global and CliniPace wins gNO contract.
Pall says its acquisition of MicroReactor Technologies (MRT) broadens its offering in the $1bn (€689m) a year global biopharmaceutical process development market.
GSK says it will start making its BPH drug Avodart (dutasteride) at its facility in Poznan, Poland when it completes a PLN70m (€17m) capacity upgrade in January next year.
Daiichi-Sankyo subsidiary Luitpold Pharmaceuticals has acquired PharmaForce, giving it a 40,000 sq ft cGMP compliant sterile manufacturing facility and a 20,000 sq ft API production plant.
The Hong Kong pharma sector should aim to adopt current World Health Organisation (WHO) GMP standards for drug manufacture within two years, according to a new report.
The US Department of Justice (DOJ) has given partial approval for Amcor’s takeover of Alcan after announcing it would now limit its review to Alcan’s Medical Flexible operations.
